Regeneron Pharmaceuticals

REGN

7 Followers

$527.78

-3.63%

-$19.89

7 August

Upcoming Earnings

Market Cap.

P/E

Overview Metrics Financials

REGN Fair Price

$900.58

Undervalued by 04.9%

To display the fair price of a share, you need to be a member of Bulios Black.

My Notes

Začít psát

Profile

Regeneron Pharmaceuticals (REGN) is an American biotechnology company specializing in the development and production of drugs for the treatment of serious diseases. With a broad portfolio of medicinal products, such as Eylea and Dupixent, Regeneron Pharmaceuticals is one of the leading players in the biotechnology sector. The company is known for its emphasis on scientific research and innovation, allowing it to bring groundbreaking treatments to market. Regeneron Pharmaceuticals is also involved in partnerships with other pharmaceutical companies and academic institutions to expand its research and development capabilities. Regeneron Pharmaceuticals (REGN) shares could be suitable for investors looking for opportunities in the biotechnology sector with a focus on innovation and scientific research.

Feed

There are no posts to show right now.